Skip to content
Dipna Pharmachem logo

Dipna Pharmachem

543594 BSE
Price unavailable

Dipna Pharmachem (DPL) share price was ₹3.76 at the 28 Oct 2026 close; market capitalisation ₹9.84 Cr; P/E (TTM) 5.37; sector Healthcare. The share price fell 81.4% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Mar 2026 quarter, revenue fell 87.1% year on year to ₹2.05 Cr and net profit was ₹0.18 Cr, against ₹0.50 Cr a year earlier (compared with Mar 2025). Promoters held 9.13% of Dipna Pharmachem in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 42/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹3.76 −16.14 −81.11% 1Y

Key Fundamentals

SMEPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹9.84 Cr
P/E (TTM)
5.37
EBITDA
₹4.99 Cr
Return on Equity
2.53%
Debt to Equity
0.21
Book Value
₹23.70
EPS (TTM)
₹0.70
52W High
₹20.50
52W Low
₹3.70

Price-based figures as of 28 Oct 2026, 15:30 IST · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,767.5035.064,24,082 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,655.0087.632,56,310 Cr15.290.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,607.8072.341,75,266 Cr9.540.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,186.70108.041,18,150 Cr22.290.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.8026.301,17,885 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,338.9034.681,11,755 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.1032.701,10,281 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Dipna Pharmachem (this company)
—5.3710 Cr0.160.00%2.53%7.25%90 Cr2 Cr
Median 8 companies₹1,767.5034.871,18,018 Cr4.710.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

42 Weak
Overall score

Data confidence 100/100

Category scores

Quality Poor 31
Returns, margins, earnings quality 22% weight
Valuation Good 66
Cheap vs sector & own history 24% weight
Growth Weak 43
Sales & profit trajectory 9% weight
Financial Health Poor 37
Solvency, leverage, coverage 9% weight
Momentum Poor 3
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company has reduced debt.
  • Stock is trading at 0.17 times its book value
  • Company's working capital requirements have reduced from 91.1 days to 55.6 days

Weaknesses

4
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding is low: 9.13%
  • Company has a low return on equity of 3.93% over last 3 years.
  • Promoter holding has decreased over last 3 years: -48.1%

Technical Indicators

Oscillators

Bullish

Bearish
1
Neutral
4
Bullish
4

Overall

Bearish

Bearish
11
Neutral
4
Bullish
4

Moving Averages

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
3.35% lower than 3Y

change over 1 year

Net Income Growth
162% higher than 3Y

change over 1 year

Cash Flow Change
-69.56%

change over 1 year

EBITDA Margin Change
40.22%

change over 1 year Operating margin 22.44% · Mar 2026

Quarterly Results

Particulars Mar 2025Dec 2025Mar 2026
Sales
15.92
53.52
2.05
Expenses
14.64
51.87
1.59
Operating Profit
1.28
1.65
0.46
OPM %
8.04%
3.08%
22.44%
Other Income
0
0
0
Interest
0.6
0.23
0.23
Depreciation
0
0
0
PBT
0.68
1.42
0.23
Tax %
26.47%
26.06%
21.74%
Net Profit
0.5
1.04
0.18
EPS (₹)
0.21
0.4
0.07
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
17
20
30
31
73
100
164
125
129
Expenses
16
20
30
31
71
98
161
121
124
Operating Profit
0
0
0
0
2
2
3
4
5
OPM %
2.4%
2.4%
1.5%
1.3%
3%
2.4%
2.1%
3%
3.9%
Other Income
0
0
0
0
0
0
0
0
0
Interest
0
0
0
0
1
1
2
2
1
Depreciation
0
0
0
0
0
0
0
0
0
PBT
0
0
0
0
2
1
1
1
4
Tax %
14%
40%
0%
60%
26%
34%
24%
32%
26%
Net Profit
0
0
0
0
1
1
1
1
3
EPS (₹)
1.2
0.6
1.2
0.4
23.4
0.37
0.45
0.4
1
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.04
0.04
0.04
0.04
0.04
12
24
24
26
Reserves
0
0
1
1
2
12
13
14
36
Borrowings
5
6
10
12
10
16
19
17
13
Other Liabilities
6
8
8
12
24
37
76
77
130
Total Liabilities
11
14
18
25
36
78
133
132
206
Fixed Assets
0
0
0
0
0
0
0
0
0
CWIP
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
Other Assets
11
14
18
25
36
78
133
132
206
Total Assets
11
14
18
25
36
78
133
132
206
Figures in ₹ Crores

Cash Flow

Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
—
—
-3
-2
3
-21
-5
-9
-18
Investing
—
—
0
0
0
0
0
0
0
Financing
—
—
3
2
-3
26
14
-4
19
Net Cash Flow
—
—
0
0
0
5
8
-13
0
Free Cash Flow
—
—
-3
-2
3
-21
-5
-9
-18
CFO/EBITDA
—
—
-693
-618
148
-893
-157
-246
-347
Figures in ₹ Crores

Ratios

Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
132
160
134
176
135
104
69
135
136
Inventory Days
112
66
70
89
34
72
86
88
144
Days Payable
142
148
105
145
123
139
172
243
375
Cash Conversion Cycle
103
78
99
120
46
38
-17
-20
-95
Working Capital Days
3
6
44
47
37
108
80
137
56
ROCE %
—
8%
5%
3%
17%
9%
7%
7%
8%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Dipna Pharmachem insights

61 extracted metrics + investor summaries across FY13–FY26.

Shareholding Pattern

Public82.70%Others8.18%Promot.9.13%As ofSep 2026

Documents

1
Concall - Feb 2025 Feb 2025
2
Concall - Nov 2024 Nov 2024
3
Concall - Aug 2024 Aug 2024
4
Concall - May 2024 May 2024
5
Concall - Feb 2024 Feb 2024

Frequently Asked Questions about Dipna Pharmachem

What does Dipna Pharmachem Ltd do?
Incorporated in 2011, Dipna Pharmachem Ltd is in the business of Pharmaceutical Trading[1]
Where is Dipna Pharmachem Ltd (DPL) listed?
Dipna Pharmachem Ltd trades under code 543594 on the BSE.
Which sector does Dipna Pharmachem Ltd belong to?
Dipna Pharmachem Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd has a market capitalisation of ₹9.84 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd trades at a PE ratio of 5.37 as of 28 Oct 2026, on earnings per share of ₹0.7, against a book value of ₹23.7 per share.
What is the 52-week high and low of Dipna Pharmachem Ltd?
Over the last 52 weeks Dipna Pharmachem Ltd has traded between ₹3.7 and ₹20.5 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd reported a return on equity of 2.53%. Its debt-to-equity ratio is 0.21.

Company Information

Incorporated in 2011, Dipna Pharmachem Ltd is in the business of Pharmaceutical Trading[1]

Website dipnapharmachem.com
Listed 2022-09-08
Face Value ₹ 10
Shares Outstanding 2,61,72,840

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/543594.md for Dipna Pharmachem Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month